Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 8/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PPP5C | P53041 | 1/20 | 0.40 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036894 | 0.89 | HTT (0.62) | HTTLMNAHRH3CNR2TSHR | |
| SCHEMBL26159917 | 0.80 | HTT (0.60) | HTTLMNAHRH3CNR2TSHR | |
| SCHEMBL21584689 | 0.79 | HTT (0.54) | HTTLMNAHRH3CNR2TSHR | |
| SCHEMBL25629645 | 0.79 | HTT (0.54) | HTTLMNAHRH3CNR2TSHR | |
| SCHEMBL12632681 | 0.79 | LMNA (0.89) | HTTLMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL14277548 | 0.77 | LMNA (1.00) | HTTLMNACNR2TSHRALDH1A1 | |
| SCHEMBL12632672 | 0.76 | LMNA (0.79) | HTTLMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL18415359 | 0.76 | HPGD (0.68) | HTTLMNAHRH3CNR2TSHR | |
| SCHEMBL4135869 | 0.76 | LMNA (0.85) | HTTLMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2075903 | 0.76 | HTT (0.81) | HTTLMNATSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190031647-A1 | RAC INHIBITORS | Geneyus LLC (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031647-A1 | RAC INHIBITORS | ARHGDIB, ARHGDIA, RAC1 | HTT 3520/4885LMNA 3071/4885HRH3 2631/4885 |
| US-10472352-B2 | Rac inhibitors | ARHGDIB, ARHGDIA, RAC1 | HTT 3520/4885LMNA 3071/4885HRH3 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.